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Cortical microinfarcts in memory clinic
patients are associated with reduced
cerebral perfusion
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Abstract
Cerebral cortical microinfarcts (CMIs) are small ischemic lesions associated with cognitive impairment and dementia.
CMIs are frequently observed in cortical watershed areas suggesting that hypoperfusion contributes to their develop-
ment. We investigated if presence of CMIs was related to a decrease in cerebral perfusion, globally or specifically in
cortex surrounding CMIs. In 181 memory clinic patients (mean age 72 9 years, 51% male), CMI presence was rated on
3-T magnetic resonance imaging (MRI). Cerebral perfusion was assessed from cortical gray matter of the anterior
circulation using pseudo-continuous arterial spin labeling parameters cerebral blood flow (CBF) (perfusion in mL blood/
100 g tissue/min) and spatial coefficient of variation (CoV) (reflecting arterial transit time (ATT)). Patients with CMIs had a
12% lower CBF (beta¼.20) and 22% higher spatial CoV (beta¼ .20) (both p< .05) without a specific regional pattern
on voxel-based CBF analysis. CBF in a 2 cm region-of-interest around the CMIs did not differ from CBF in a reference
zone in the contralateral hemisphere. These findings show that CMIs in memory clinic patients are primarily related to
global reductions in cerebral perfusion, thus shedding new light on the etiology of vascular brain injury in dementia.
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Introduction
Cerebral cortical microinfarcts (CMIs) are small ische-
mic lesions visible on neuropathological examination
and also detectable in vivo with high ﬁeld strength mag-
netic resonance imaging (MRI).1,2 CMIs commonly
occur in patients with stroke and dementia and their
contribution to vascular cognitive impairment is
increasingly recognized.3
Although the pathophysiological mechanisms are
not fully clear, CMIs probably have multiple causes.
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CMIs may result from small vessel disease (SVD),
including cerebral amyloid angiopathy (CAA) and
hypertensive SVD.3 Moreover, CMIs can also result
from thromboemboli due to large vessel or cardiac dis-
ease.3,4 An interesting observation is that CMIs appear
to be frequently located in the cortical watershed
regions both in neuropathology5–7 and MRI studies.8,9
Watershed regions are located at the junction of two
vascular territories and are therefore sensitive to hypo-
perfusion.10 These ﬁndings suggest that hypoperfusion
might play a role in the pathophysiology of CMIs.
Arterial spin labeling (ASL) is a non-invasive MRI
perfusion technique, whereby blood is magnetically
labeled in the cervical arteries. After a short post-
labeling delay, a cerebral blood ﬂow (CBF) map is
obtained from the ASL signal in brain tissue.36
Due to this ﬁxed delay, the CBF maps may become
inaccurate when blood ﬂowing towards the brain is
slowed – prolonged arterial transit time (ATT) – for
example in elderly and patients with cerebrovascular
disease.11 Recently, the ASL-derived parameter spatial
coeﬃcient of variation (CoV) has been introduced that
approximates ATT and is suitable for individuals with
compromised CBF.12
In this study, we aim to determine if presence of
CMIs is related to decreased cerebral perfusion,
assessed with pseudo-continuous ASL (pCASL) CBF
and spatial CoV in memory clinic patients; and if per-
fusion is speciﬁcally reduced locally around CMIs.
Methods
Population
This study involved patients who attended the memory
clinics of the National University Hospital or St. Luke’s
Hospital in Singapore and had received one of the fol-
lowing diagnoses13: (1) No cognitive impairment (NCI):
patients without objective cognitive impairment on
formal neuropsychological tests or functional loss. (2)
Cognitive impairment – no dementia (CIND) with (2 a)
or without (2 b) a history of stroke: included patients
who were impaired in at least one cognitive domain
on neuropsychological testing, but did not meet the
DSM (4th edition) criteria for dementia. Ischemic
stroke was assessed based on medical history and con-
ﬁrmed by neuroimaging; patients with a hemorrhagic
stroke were excluded from participation. Patients with
dementia received an etiological diagnosis on the basis
of internationally established criteria for (3) Alzheimer
dementia (AD)14 and (4) Vascular dementia.15 Patients
with other diagnoses (e.g. Frontotemporal Dementia),
signiﬁcant neurological comorbidities or loss of func-
tional independence, were excluded from participation.
All patients underwent a standardized clinical
examination, 3-T MRI including ASL and neuropsy-
chological testing.4,13 For the present study, we
included all patients recruited between December
2010 and September 2013 and had structural MRI
and ASL sequences of suﬃcient quality.
Ethical approval for this study was obtained from
the National Healthcare Group Domain-Speciﬁc
Review Board (DSRB). The study was conducted in
accordance with the Declaration of Helsinki. Written
informed consent was obtained, in the preferred lan-
guage of the patients, by bilingual study coordinators
before recruitment into the study. Consent for patients
lacking capacity was provided by their legal represen-
tative, as allowed by the DSRB.
Level of education was classiﬁed into four cate-
gories: no education, primary education, secondary
education, or tertiary education. The following vascular
risk factors were recorded: hypertension was deﬁned as
a previous diagnosis of hypertension, or use of antihy-
pertensive medication; diabetes mellitus was deﬁned
as previous diagnosis of diabetes mellitus, or use of
anti-diabetic medication; hyperlipidemia was deﬁned
as previous diagnosis of hyperlipidemia, or use of cho-
lesterol-lowering medication. Obesity was deﬁned as
a body mass index >25. A history of cardiac disease
was deﬁned as a previous diagnosis of myocardial
infarction, congestive heart failure, atrial ﬁbrillation,
or intervention procedures such as angioplasty, or
stenting. A history of stroke was based on self-report.
MRI protocol
Patients were scanned on a 3-T MRI (Siemens
Magnetom Trio Tim system) with a 32-channel receiver
head-coil. The structural imaging protocol included a
three-dimensional (3D) T1, 2D T2, T2*-weighted and
ﬂuid-attenuated inversion recovery (FLAIR) sequences
(see eTable 2 for scanner-settings). pCASL images were
acquired with labeling duration 1738ms, post-labeling
delay 1500ms, and gradient-echo echo planar imaging
of TR/TE 4000/9ms, GRAPPA factor 3, 3.0 3.0
5.0mm3 voxels. ASL scans consisted of 23 pairs of
images (control–labeled). CBF values were calculated
voxel-wise from the mean diﬀerences of these two
images. For each patient, the ASL protocol was carried
out twice with a 1-h interval; CBF was averaged over
the two sessions, unless one of the scan sessions was
disregarded due to insuﬃcient quality.
MRI ratings
The following MRI markers were rated: Microbleeds
were assessed using the Brain Observer MicroBleed
Scale.16 The presence of large (i.e. >5mm) cortical
infarcts, subcortical infarcts (i.e. subcortical infarct
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and/or lacunar infarcts), and white matter hyperinten-
sities (WMHs) were rated according to the STRIVE
criteria.17 Infarct and WMH volumes were manually
segmented on FLAIR and T1-weighted images using
an in-house developed tool incorporated in MeVisLab
(MeVis Medical Solutions AG, Bremen, Germany).
Gray matter (GM), white matter, and cerebrospinal
ﬂuid were obtained from the T1-weighted image using
the uniﬁed tissue segmentation approach18 imple-
mented in Statistical Parametric Mapping (SPM)
(Wellcome Trust Centre for Neuroimaging, University
College London, UK) from which total brain volume
and intracranial volume were quantiﬁed. The presence
of intracranial stenosis on the 3D time-of-ﬂight MRA
was deﬁned as a narrowing exceeding 50% of the lumi-
nal diameter of the posterior cerebral, middle cerebral,
and anterior cerebral artery and the intracranial part of
vertebral, basilar, and internal carotid artery.19
CMIs were rated by visual inspection by a single
experienced rater (SvV). In line with previously vali-
dated criteria, CMIs were obliged to be <5mm in the
largest dimension and hypointense on 3D T1-weighted
images and hyperintense or isointense on FLAIR and
T2-weighted images.2 Lesions had to be strictly intra-
cortical, perpendicular to the cortical surface and dis-
tinct from perivascular spaces. Moreover, a lesion was
discarded as CMI if the area was considered part of a
larger infarction. There was a good to excellent intra-
rater agreement (Intraclass correlation
coeﬃcient¼ 0.97; Dice’s similarity coeﬃcient¼ 0.65)
on the CMI ratings of this cohort. We have previously
published the clinical correlates of CMIs in this speciﬁc
cohort.13 A 3D representation of all CMIs in the cohort
was conﬁgured by registering the lesions to the MNI152
standard brain (Figure 1). We used an in-house devel-
oped watershed atlas as overlay. This atlas was based
on the average territorial ASL maps from individuals
with steno-occlusive disease.20 The watershed areas
were deﬁned as overlapping perfusion territories
across subjects.
ASL
ASL post-processing was performed with the
ExploreASL toolbox, an in-house developed toolbox
based on SPM and Matlab7.12.0 (MathWorks,
Nattick, MA).21 Post-processing included motion cor-
rection and rigid body registration of the CBF map to a
GM map and normalized into common space through
the T1-weighted images using Diﬀeomorphic
Anatomical Registration analysis using Exponentiated
Lie algebra (DARTEL)22 using CAT12.23 From the
CBF map, two ASL parameters were acquired within
a pGM> 0.7 GM region-of-interest (ROI): CBF and
Spatial CoV. CBF reﬂects perfusion in mL blood/
100 g tissue/min. To avoid systematic bias in patients
with more severe atrophy, partial volume corrections
was applied to the CBF (CBFpvc) using local linear
regression within a 3D kernel based on the CAT12
tissue partial volume maps.24 Spatial CoV is a novel
ASL parameter particularly suitable for individuals
with severely prolonged ATT, such as patients with a
vascular brain disease in which CBF sometimes cannot
be readily measured. It serves as a proxy of ATT and is
calculated by dividing the SD of the CBF by the mean
CBF. Additional details regarding spatial CoV have
been published previously.12
Global CBF and spatial CoV were obtained using a
GM mask of anterior brain circulation only (i.e. the
internal carotid artery ﬂow territory, not the posterior
circulation as supplied by the vertebrobasilar system),
as acquisition parameters were not favorable for the
longer arrival time in the posterior circulation. Mean
cortical GM CBF was calculated from the intersection
of the watershed ROI obtained from a watershed
atlas20 – shown in Figure 1 – and the subject-wise
GM mask. A voxel-based analysis of the cortical GM
CBF diﬀerences between patients with and without
CMIs was performed in SPM. CBF maps were
smoothed with a 6-mm full width at half maximum
Gaussian kernel.
Figure 1. 3D representation of cerebral cortical microinfarcts
with watershed overlay. Superior view of a 3D representation of
cerebral cortical microinfarcts (black dots) in the cohort pro-
jected on an MNI-standard brain. The red overlay signifies the
cortical watershed regions.20
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Individual CMI ROIs composed of a 2-cm diameter
sphere around the CMIs. The diameter was set at 2 cm,
as a trade-oﬀ between spatial speciﬁcity requiring the
smallest possible diameter and signal to noise ratio/
resolution of ASL, which puts boundaries to the min-
imum diameter that can be used.Within the sphere only
the cortical GM was considered for partial volume cor-
rected CBF assessment. A comparative ROI was cre-
ated on the same anatomical location in the
contralateral hemisphere. CMI ROIs were excluded
from analysis if they overlapped (either in the ipsi- or
contralateral hemisphere) with another ROI or larger
infarct, resulting in a total of 67 CMI ROIs in 35
patients. Figure 2 provides a visual representation of
the ROI analysis.
Visual quality assessment of the ASL scans was per-
formed by two independent raters (DF and HM) based
on visual evaluation. Scans were classiﬁed according to
one of four categories (Figure 3): (1) Unusable was
applied to scans that were incomplete, had labeling
errors, or severe motion artifacts (n¼ 53). (2)
Angiogram for scans with predominantly vascular con-
trast and no or minimal tissue perfusion (n¼ 33).12 (3)
Acceptable scans which had minor vascular contrast or
motion artifacts and reasonable tissue perfusion
(n¼ 58), or (4) good (n¼ 90). Patients with unusable
scans were excluded from analysis. All other patients
were analyzed, but the 33 patients with angiogram-
classiﬁed ASL scans were not included in the CBF ana-
lysis, as the lack of tissue perfusion causes unreliable
interpretation.12
Statistical analysis
Diﬀerences in baseline characteristics between patients
with and without CMIs were compared with an inde-
pendent t-test (for continuous normally distributed
data), -square test (for proportions), and Mann–
Whitney U test (for continuous, non-normally distribu-
ted data). WMH volume and spatial CoV data were log
transformed. The relation between CMI presence (inde-
pendent variable) and CBF, CBFpvc, and spatial CoV
(dependent variable) was assessed using linear regression
in model 1. In model 2, age and sex were entered as
covariates. In model 3, we performed additional
explorative analyses where individual and combined
vascular risk factors were added as covariates to model
2 and in model 4 where individual and combined neuro-
imaging markers were added as covariates to model 2.
Models are presented with B-values representing the
mean diﬀerence (and 95% conﬁdence interval) in cere-
bral perfusion between patients with and without CMIs.
Within the patients with CMIs, Spearman’s rank correl-
ation was used to determine the relationship between the
Figure 2. Quality assessment method of the ASL scans, including quality criteria and example images.
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total number of CMIs per patient to the CBF, CBFpvc,
and spatial CoV. For the voxel-based analysis, signiﬁ-
cant clusters of voxels were identiﬁed using a primary
cluster-forming threshold of p< .001, family-wise
corrected for cluster sizes corresponding to p< 0.05.
For the CMI ROI analysis, CBF was compared between
the ROIs in the ipsi- and contralateral hemispheres in a
paired (within subjects) t-test. All data were analyzed
using IBM SPSS statistics (version 25) and a
p-value< .05 was considered statistically signiﬁcant.
Results
Demographics and CMI occurrence
Of the 234 patients, 53 (23%)were excluded due to insuf-
ﬁcient quality of the ASL scan. The excluded patients
were on average older and had more severe cognitive
impairment (i.e. a lower mini-mental state examination
and a higher proportion of patients with diagnosis
dementia) and a higher CMI burden (eTable 1). Of the
remaining 181 patients included in the spatial CoV ana-
lyses, 148 patients – without angiogram like ASL scans –
were suitable for CBF analyses. The mean age of these
181 patients was 72 years (SD 9), 51%were male and the
majority (80%) of Chinese ethnicity. Of these patients,
41% was diagnosed with dementia, 43% with CIND,
and 16%withNCI. The 33 patients who were unsuitable
for the CBF analysis due to angiogram qualiﬁed ASL
scans had a higher proportion of males and a higher CM
burden (eTable 1).
A total of 179 CMIs were detected in 50 (28%) of the
181 patients. The number of CMIs per patient ranged
between 1 and 43, and 23 patients (46%) had multiple
CMIs. Patients with CMIs were proportionally often
male (p¼ .063) and had a higher burden of vascular
risk factors and cerebrovascular disease (Table 1).
Figure 1 displays a 3D spatial topographical represen-
tation of all CMIs in the cohort. Visual inspection sug-
gests a clustering of CMIs in fronto-parietal areas
without evident predilection for the cortical watershed
regions.
Perfusion in patients with and without CMIs
CMI presence was associated with a 12% reduced cor-
tical CBF (eﬀect size d¼ 0.49, p¼ .016), a 9% reduced
partial volume corrected CBF (CBFpvc) (eﬀect size
d¼ 0.41, p¼ .044) and a 22% increased spatial CoV
(eﬀect size d¼ 0.46, p¼ .006) in the anterior circulation
(Figure 4; Table 2 model 1). When corrected for age
and sex, results remained similar for CBF (p¼ .038)
and spatial CoV (p¼ .039), but attenuated for CBFpvc
(p¼ .078) (Table 2 model 2). The individual and com-
bined vascular risk factors had a marginal eﬀect on
the relationship between CMI presence and cerebral
perfusion (Table 2 model 3). Similarly, the individual
neuro-imaging markers, including intracranial stenosis,
also had a marginal eﬀect on the relationship between
CMIs presence and cerebral perfusion, with the excep-
tion of total brain volume and WMHs that both atte-
nuated the strength of the association between CMIs
and perfusion measures (Table 2 model 4). Moreover,
in the model with all neuro-imaging markers combined,
the relationship between CMI and perfusion measures
disappeared. Within the patients with CMIs, a higher
number of CMIs per patient was modestly correlated to
a higher spatial CoV (Rho¼ .27, p¼ .057), but not to
CBF (Rho¼.06, p¼ .752) or CBFpvc (Rho¼.07,
p¼ .699). With respect to the perfusion in the watershed
Figure 3. Cerebral perfusion in patients with and without cerebral cortical microinfarcts (CMIs). Boxplots of the mean and standard
deviation of the cerebral blow flow (CBF), partial volume corrected CBF and spatial coefficient of variation (CoV) in the anterior
circulation in patients with and without CMIs. P-values are reported on the uncorrected differences between patients with and
without CMIs.
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Age, mean (SD), years 71.5 (9.3) 72.6 (8.8) .464
No. (%) males 61 (47) 31 (62) .063
Ethnicity, no. (%) Chinese 107 (82) 37 (74) .251
Education, median (IQR) (4 levels) 2 (1–3) 2 (1–3) .357
Vascular risk factors
Hypertension, no. (%) 92 (70) 43 (86) .029
Hypercholesterolemia, no. (%) 82 (63) 44 (88) .001
Diabetes, no. (%) 46 (35) 25 (50) .067
Current smoking, no. (%) 11 (8) 7 (14) .260
Obesity (4 missing), no. (%) 4 (3) 5 (10) .062
History of stroke, no. (%) 44 (34) 25 (50) .042
Cardiac disease, no. (%) 19 (15) 20 (40) <.001
Cognitive performance
CDR median (IQR) 0.5 (0–1) 0.75 (0.5–1) .238
MMSE, mean (SD) 22.1 (5.8) 20.6 (5.8) .129
Clinical diagnosis, no. (%)
NCI 25 (19) 4 (8) .135
CIND 56 (43) 21 (42)
Dementia 50 (38) 25 (50)
Neuro-imaging markers
Total brain volume, mean (SD), % of TIV 64.8 (5.7) 62.1 (6.2) .006
WMH volume, median (IQR), mL 8.3 (3.3–19.8) 12.1 (5.4–29.7) .010 a
Presence of cortical infarcts >5mm, no. (%) 8 (6) 17 (34) <.001
Presence of subcortical infarcts, no. (%) 32 (24) 22 (44) .010
Presence of microbleeds, no. (%) 66 (50) 35 (70) .017
Presence intracranial stenosis (4 missing) 23 (18) 15 (31) .053
CMI: cerebral cortical microinfarct; CDR: clinical dementia rating scale; MMSE: mini-mental state examination; NCI: no cognitive
impairment; CIND: cognitive impairment – no dementia; TIV: total intracranial volume; WMH: white matter hyperintensity.
Obesity was defined as a body mass index >25.
aWMH volume was entered into the analysis after a logarithmic transformation of the data.
Figure 4. Voxel based analysis of the differences in cerebral blood flow between the group of patients with cortical microinfarct
compared to the group of patients without cortical microinfarcts. Significant clusters (cluster threshold of p<.001, family wise
corrected to <0.05) are shown in yellow to red, non-significant clusters are shown in green.
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regions, the diﬀerence in CBF (beta¼.17, p< .05) and
CBFpvc (beta¼.16, p¼ .058) between patients with and
without CMIs in these regions was of similar magnitude
as the whole anterior brain circulation. To determine the
spatial pattern of hypoperfusion in patients with CMIs
compared to patients without CMIs, a voxel-based ana-
lysis of CBF signal was performed, which showed a rela-
tively homogeneous pattern of hypoperfusion over the
whole cortex (Figure 5).
Perfusion around CMIs
Mean CBF in 2-cm cortical GM ROIs around the
CMIs (CBF¼ 73.1mL/100 g tissue/min, SD 26.7) was
not diﬀerent from the CBF of the ROI in the contra-
lateral reference regions (CBF¼ 73.0mL/100 g tissue/
min, SD 28.6) (p¼ .97).
Discussion
We found that presence of CMIs in memory clinic
patients was associated with reduced cerebral perfusion
throughout the anterior circulation, but that perfusion
in the cortex directly surrounding CMIs was not spe-
ciﬁcally aﬀected.
Table 2. Association between CMI presence and cerebral perfusion adjusted for covariates.
CBF (N¼ 148)
B (95% CI) p
CBFpvc (N¼ 148)
B (95% CI) p
Spatial CoV (N¼ 181)
B (95% CI) p
Model 1: CMI presence 6.1 (11.1; 1.2) .016 6.5 (12.9; .2) .044 .08 (.02; .14) .006
Model 2: CMIþ age, sex 5.0 (9.7; .2) .038 5.6 (11.9; .6) .078 .06 (.003; .11) .039
Model 3: CMIþ age, sexþ
Hypertension 4.6 (9.3; .1) .054 5.1 (11.4; 1.1) .106 .05 (.005; .10) .079
Hypercholesterolemia 4.4 (9.3; .4) .073 4.8 (11.2; 1.6) .143 .05 (.006; .10) .082
Diabetes 4.5 (9.3; .2) .061 5.3 (11.7; 1.0) .098 .06 (.003; .11) .040
Current smoking 5.2 (9.9; .4)) .033 5.8 (12.1; .5) .072 .05 (.001; .11) .045
Obesity 5.0 (9.9; .1) .044 6.2 (12.7; .4) .064 .06 (.004; .11) .034
History of stroke 5.7 (10.5; 1.0) .018 4.9 (11.2; 1.4) .126 .05 (.001; .11) .047
Cardiac disease 4.5 (9.2; .3) .065 6.4 (12.7; .1) .048 .05 (.01; .10) .122
All vascular risk factors 4.8 (9.8; .3) .066 5.7 (12.5; 1.0) .096 .05 (.005; .11) .075
Model 4: CMIþ age, sexþ
Total brain volume 3.7 (8.2; .8) .110 4.5 (10.7; 1.7) .154 .04 (.01; .10) .104
WMH volumea 3.1 (7.8; 1.7) .200 3.6 (10.0; 2.8) .265 .03 (.02; .09) .210
Presence of cortical infarcts 5.0 (10.0; .1) .045 5.6 (12.2; .9) .090 .05 (.003; .11) .064
Presence of subcortical infarcts 4.6 (9.5; .2) .059 5.0 (11.4; 1.4) .122 .05 (.001; .11) .048
Presence of microbleeds 4.2 (8.9; .6) .086 4.4 (10.7; 1.9) .171 .05 (.004; .10) .069
Presence intracranial stenosis 4.4 (9.2; .4) .073 5.0 (11.4; 1.5) .128 .05 (.003; .10) .064
All imaging markers 1.1 (6.0; 3.9) .670 1.2 (8.1; 5.6) .727 .02 (.04; .07) .581
CBF: cerebral blood flow; CBFpvc: partial volume corrected cerebral blood flow; spatial CoV: spatial coefficient of variation of the cerebral blood flow;
CMI: cerebral cortical microinfarct; WMH: white matter hyperintensity. Data presented as B: mean difference between patients with and without CMIs
and the 95% confidence interval. Model 1: unadjusted; model 2: adjusted for age and sex; model 3: adjusted for age, sex and each individual vascular risk
factor added separately; model 4: adjusted for age, sex and each individual neuro-imaging marker added separately.
aWMH volume was entered into the analysis after a logarithmic transformation of the data.
Figure 5. Local CBF analysis using CMI ROIs. Cerebral blood
flow (CBF) within a Region-of-Interest (ROI), composed of a 2cm
diameter sphere (green area) around the cortical microinfarcts
(CMIs) (red dot), was compared to the CBF within an ROI on the
same anatomical location in the contralateral hemisphere (purple
area).
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The two ASL parameters studied (i.e. CBF and
spatial CoV) congruently showed that cerebral perfu-
sion was aﬀected in patients with CMIs. Previous
studies had already provided circumstantial evidence
of a link between CMIs and perfusion. Post-mortem
subcortical CMIs were found to relate to ante-
mortem blood pressure decline on serial blood pres-
sure assessments, possibly translating in reduced cere-
bral perfusion pressure.25 Furthermore, both post-
mortem5–7 and MRI studies8,9 have suggested that
CMIs might have a predilection for the cortical
watershed areas. This hypothesis could, however,
not be conﬁrmed in the current study. Although clus-
tered in the fronto-parietal cortex, we observed no
evident predilection of CMIs in the watershed areas,
as deﬁned by a previously established ASL atlas.
These diﬀerent ﬁndings might be attributed to the
study population, as both CMI occurrence and eti-
ology are known to vary in diﬀerent contexts.
Additionally, previous neuropathological studies5–7
allow for detection of much smaller (i.e. <1mm)
CMIs that could have a diﬀerent topographical local-
ization. Future research is encouraged to further
explore this on ultra-high ﬁeld MRI, which allows
for detection of intermediate size CMIs.
In line with our observations in CMIs, the presence
of other manifestations of SVD on MRI has been
linked to reductions in cerebral perfusion. There is,
for example, a growing body of – mostly cross-sec-
tional – studies reporting a relation between WMHs
and reduced perfusion.26 Of note, perfusion is also
found to be locally reduced within WMH lesions27and
longitudinal studies suggested that hypoperfusion
probably precedes the formation of WMHs.28,29 The
presence of microbleeds is also reported to be related
to globally reduced perfusion.30 Although we are not
aware of studies exploring perfusion directly around
the microbleeds, the previous study indicates that
hypoperfusion is not restricted to the preferential par-
ietal–occipital location of cortical microbleeds in
CAA.
Although perfusion may be reduced at the lesion
sites, particular for WMHs, the consistent ﬁnding for
the diﬀerent manifestations of SVDs is that they pre-
dominantly associate with globally reduced cerebral
perfusion. The question is therefore what mechanisms
tie these small focal lesions to reduced global perfusion.
First, there could be a causal link, where hypoperfusion
directly induces CMIs. In that scenario, CMIs may
occur at sites that reach a critical perfusion threshold
or that are exposed to a second pathophysiological
mechanism. Disturbances more proximal in the vascu-
lar tree, such as cardiac pump dysfunction4 or stenosis
or occlusion of the cervical and intracranial
arteries,13,31 could certainly contribute towards
reaching a critical perfusion threshold. In this study,
we found a marginal eﬀect of intracranial stenosis on
the relation between CMIs presence and perfusion.
Unfortunately, no data on extracranial stenosis or car-
diac pump function were available in this cohort.
Evidence for an interaction with a second pathophysio-
logical mechanism comes from a CAA mouse model
study, which showed that mice subjected to chronic
hypoperfusion not only showed accelerated deposition
of leptomeningeal amyloid but also a markedly higher
CMI burden than CAA mice with normal cerebral
perfusion.32
Another possibility is that both reduced perfusion
and CMIs are due to shared etiologies, without being
directly causally linked to each other. Such shared
etiologies could include SVD, where restriction of
vessel lumen by arteriolosclerosis, CAA, loss of
autoregulation, blood–brain barrier leakage, and
inﬂammation could aﬀect perfusion as well as
induce CMIs.33 Explorative analysis in this study
showed that entering other imaging manifestations
of SVDs, especially WMHs, together with CMIs in
the statistical models, attenuated the association
between CMI presence and perfusion. Even shared
vascular risk factors, such as hypertension, could
contribute to both independently. However, our
exploratory analyses indicated that both individual
and combined vascular risk factors only marginally
aﬀected the relationship between CMIs and perfu-
sion. It is highly likely that the abovementioned
mechanisms coincide and even interact. For exam-
ple, it has been suggested that reduced arterial ﬂow
can prompt the formation of thrombo-emboli due to
impaired wash-out,34 providing additional mechan-
isms for CMI development. We therefore encourage
future studies to further investigate the underlying
mechanisms tying CMIs to cerebral perfusion. This
could include zooming in on clinical populations
known to exhibit compromised cerebral perfusion,
such as patients with heart failure or severe carotid
artery stenosis. Moreover, the mediating role of
SVDs could be further explored by assessing inter-
relations with other imaging manifestations of
SVDs, in particular WMH, but also by using novel
measures of small vessel function and blood–brain
barrier function, that may provide more direct indi-
cations of the condition of the small vessels in SVD,
independent of downstream lesions.35
The interaction between CMIs and reduced cerebral
perfusion clearly carries clinical signiﬁcance. Over the
years, a robust relationship has been demonstrated
between CMIs and cognitive impairment, yet currently
without clear prospect of treatment.3 The current study
highlights the importance of cerebral perfusion as
potential therapeutic target.
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This study has several strengths and limitations.
It involved a heterogeneous memory clinic cohort
with a broad range of cognitive symptoms, strengthen-
ing results as it reﬂects daily clinical practice. Although
CMIs were rated according to validated criteria, the
limited sensitivity of 3-T MRI needs to be acknowl-
edged, as it allows detection of only a fraction of the
CMIs visible on 7-T or neuropathological examin-
ation.2 It remains unclear how these smaller CMIs
relate to cerebral perfusion. A watershed atlas based
on a group-averaged territorial ASL map was used in
this study. However, it must be acknowledged that
there is a large inter-individual variation in the size
and exact location of the watershed regions. Major
challenges of the ASL technique include a low signal-
to-noise ratio and problematic application in patients
with prolonged ATT.36 As a result, we applied rela-
tively large ROIs of 2 cm around the CMIs, while the
area of perfusion restriction could in fact be smaller.
Finally, we had to exclude a relatively high (23%) pro-
portion of severely aﬀected patients due to poor ASL
scan quality. We partially resolved this issue by using
the novel ASL parameter spatial CoV and improve
ASL quality by repeating the ASL protocol twice.
Conclusion
CMI presence was associated with decreased cerebral
perfusion in the anterior circulation of memory clinic
patients, but perfusion in the region directly surrounding
CMIs did not appear selectively aﬀected. Hence, in line
with other manifestations of SVDs, CMIs predominantly
relate to a global reduction in perfusion. This could be
the result of a direct causal relation of hypoperfusion on
CMI development or shared underlying mechanisms,
such as SVD, proximal vascular pathology, and vascular
risk factors, or a combination of all. Further unravelling
the link between CMIs and perfusion reduction will sig-
niﬁcantly contribute to understanding of vascular cogni-
tive impairment and has important clinical implications
with respect to treatment.
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